Provided by Tiger Trade Technology Pte. Ltd.

Fulcrum Therapeutics

12.08
-0.4200-3.36%
Post-market: 12.080.00000.00%17:59 EST
Volume:768.91K
Turnover:9.40M
Market Cap:796.92M
PE:-10.57
High:12.66
Open:12.47
Low:12.02
Close:12.50
52wk High:15.74
52wk Low:2.32
Shares:65.97M
Float Shares:39.39M
Volume Ratio:0.32
T/O Rate:1.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1430
EPS(LYR):-0.1569
ROE:-31.21%
ROA:-20.63%
PB:4.02
PE(LYR):-76.99

Loading ...

Fulcrum Therapeutics Grants Stock Options to New Employee Under Inducement Plan

Reuters
·
Dec 06

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Dec 06

Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025

GlobeNewswire
·
Dec 02

Fulcrum Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Nov 24

Buy Rating for Fulcrum Therapeutics Driven by Promising PIONEER Study Results and Market Potential of Pociredir

TIPRANKS
·
Nov 24

Fulcrum Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $18 From $12

THOMSON REUTERS
·
Nov 24

Director Robert J. Gould Reports Sale of Fulcrum Therapeutics Inc. Common Shares

Reuters
·
Nov 22

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Nov 20

Fulcrum Therapeutics: Promising Sickle Cell Treatment with Pociredir Outshines Competitors

TIPRANKS
·
Nov 20

Oppenheimer not surprised by Agios data, continues to favor Fulcrum approach

TIPRANKS
·
Nov 20

Fulcrum Therapeutics Grants Stock Options to New Employees Under Inducement Plan

Reuters
·
Nov 08

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Nov 08

Fulcrum Therapeutics Inc : Stifel Resumes Coverage With Buy Rating; Target Price $20

THOMSON REUTERS
·
Nov 06

Fulcrum Therapeutics resumed with a Buy at Stifel

TIPRANKS
·
Nov 06

Fulcrum Therapeutics Unveils New PIONEER Trial Data for Pociredir in Sickle Cell Disease

Reuters
·
Nov 04

Stock Track | Fulcrum Therapeutics Soars 5.34% as Analysts Raise Price Targets Following Q3 Earnings

Stock Track
·
Oct 30

Fulcrum Therapeutics Price Target Raised to $16.00/Share From $12.50 by Piper Sandler

Dow Jones
·
Oct 30

U.S. RESEARCH ROUNDUP- Alphabet, Boeing, KLA

Reuters
·
Oct 30

Fulcrum Therapeutics Inc : Piper Sandler Raises Target Price to $16 From $12.50

THOMSON REUTERS
·
Oct 30

Fulcrum Therapeutics Reports Q3 2025 Progress and Financials

TIPRANKS
·
Oct 30